BE assessment regarding first time point Cmax [Study As­sess­ment]

posted by Erkin – Turkey, 2018-12-28 08:29  – Posting: # 19717
Views: 3,003

Dear Mann,

I've found the following on page 298 of "Generic Drug Product Development - Solid Oral Dosage Forms" by Leon Shargel & Isadore Kanfer":

First point Cmax: Do any of the concentrations vs. time profiles exhibit first-point Cmax (i.e., the first sample collected is the Cmax value)?
If so, were 3 to 5 samples collected within the first hour and was one of these collected between 5 and 15 minutes post-dose?
If these early samples were collected, no change in data analysis is warranted.
If these early samples were not collected, then those subjects with first point Cmax values should be dropped from the primary statistical analysis.


I couldn't find the reference from EMA or FDA about dropping the subjects. I've contacted to Dr. Leon Shargel via e-mail and asked him the same question.

I will post here, as soon as he replied me.

Regards,
Erkin

Complete thread:

Activity
 Admin contact
20,255 posts in 4,263 threads, 1,398 registered users;
online 13 (0 registered, 13 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 09:16 CET

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5